N
Niels W.C.J. van de Donk
Researcher at VU University Amsterdam
Publications - 181
Citations - 10323
Niels W.C.J. van de Donk is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Multiple myeloma & Daratumumab. The author has an hindex of 39, co-authored 181 publications receiving 7427 citations. Previous affiliations of Niels W.C.J. van de Donk include Harvard University & Utrecht University.
Papers
More filters
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Journal ArticleDOI
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W.C.J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser +14 more
TL;DR: Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Journal ArticleDOI
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld,Hervé Avet-Loiseau,Sagar Lonial,Saad Z. Usmani,David S. Siegel,Kenneth C. Anderson,Wee Joo Chng,Philippe Moreau,Michel Attal,Robert A. Kyle,Jo Caers,Jens Hillengass,Jesús F. San Miguel,Niels W.C.J. van de Donk,Hermann Einsele,Joan Bladé,Brian G.M. Durie,Hartmut Goldschmidt,Maria-Victoria Mateos,Antonio Palumbo,Robert Z. Orlowski +20 more
TL;DR: Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-based survival and progression- free survival int( 4;14), del( 17/17 p), and t(14;16), and gain(1q).
Journal ArticleDOI
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau,Michel Attal,Cyrille Hulin,Bertrand Arnulf,Karim Belhadj,Lotfi Benboubker,Marie C. Béné,Annemiek Broijl,Hélène Caillon,Denis Caillot,Jill Corre,Michel Delforge,Thomas Dejoie,Chantal Doyen,Thierry Facon,Cécile Sonntag,Jean Fontan,Laurent Garderet,Kon-Siong Jie,Lionel Karlin,Frédérique Kuhnowski,Jérôme J. Lambert,Xavier Leleu,Pascal Lenain,Margaret Macro,Claire Mathiot,Frédérique Orsini-Piocelle,Aurore Perrot,Anne-Marie Stoppa,Niels W.C.J. van de Donk,Soraya Wuilleme,Sonja Zweegman,Brigitte Kolb,Cyrille Touzeau,Murielle Roussel,Mourad Tiab,Jean-Pierre Marolleau,Nathalie Meuleman,Marie-Christiane Vekemans,Matthijs Westerman,Saskia K. Klein,Mark-David Levin,Jean Paul Fermand,Martine Escoffre-Barbe,Jean-Richard Eveillard,Reda Garidi,Tahamtan Ahmadi,Sen Zhuang,Christopher Chiu,Lixia Pei,Carla de Boer,Elena Smith,William Deraedt,Tobias Kampfenkel,Jordan M. Schecter,Jessica Vermeulen,Hervé Avet-Loiseau,Pieter Sonneveld +57 more
TL;DR: D-VTd before and after autologous stem-cell transplantation improved depth of response and progression-free survival with acceptable safety and CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
CD38 antibodies in multiple myeloma: back to the future.
TL;DR: Deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors, and CD38-targeting antibodies are generally well tolerated and induce partial response or better in heavily pretreated MM patients as monotherapy.